Search

Hyperthyroidism like cause of anemia is rare, normally in this pathology there is a increase of the erythropoiesis secondary to the cellular hypoxia causes by the increase of the basal metabolism. We have revised the histories of diagnostical hyperthyroidism in our center, which presented anemia, we found four cases which presented anemia. All of them were women with associated heart disease. It is believe that this anemia is related with the patients age and the evolution time of the hyperthyroidism. We concluded after the bone marrow studies that the anemia of hyperthyroidism is a anemia of chronic disease with light reactive plasmocytosis.

In this open study, 210 patients from both sexes, age above 60 years and diagnosis of AHT, were included. All patients were treated, following the washing-out phase, with a calcium antagonist dihydropyridine: nicardipine, at a doses of 60 mg/day for 12 weeks. A significant reduction in SAP (from 168.97 to 152.25 mm Hg.) and DAP (from 98.17 to 87.63 mm Hg.) was observed, without modifications in the cardiac rate. In addition, a low incidence of adverse effects and a high biological tolerance of the drug has been demonstrated during the whole study.

Seventy one mild to moderate essential hypertensive patients receiving out-patient treatment with Captopril--inhibitor of the conversion enzyme--during a period of six months, are studied. The therapeutic goal (DAP less than 95 mm Hg.) was reached in 88% of the cases, with just a single Captopril dose of 50 mg/day in 42 patients (59.1%). AP decreased from 174.2/100.2 mm Hg. to 149.2/84.0 mm Hg. (p less than 0.001). Any significant changes in heart rate nor in body weight were observed. Side effects were rare (just in two patients), although their intensity determined in both cases the interruption of treatment. Finally, and improvement in the metabolic profile of patients was observed, with reduction in glucose, cholesterol, triglycerides and uric acid at the end of the study.